Comparative Trial of Canyon Pharmaceuticals's Iprivask (Desirudin) with Standard of Care Shows Favorable Outcomes for Thrombosis Prophylaxis in Surgery Patients with HIT

PARSIPPANY, N.J.--(BUSINESS WIRE)--Results of the first randomized, head-to-head comparison of direct thrombin inhibitors (DTIs) in patients with heparin-induced thrombocytopenia (HIT) were presented at the Hemophilia & Thrombosis Research Society 2010 Scientific Symposium in Chicago, Illinois on April 15. The PREVENT-HIT study found that desirudin warrants further investigation as an alternative treatment for thrombosis prophylaxis in surgery patients with HIT.